TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02499913

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: breath alcohol monitoring
Description: Daily breath alcohol monitoring

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: breath alcohol monitoring
Description: Daily breath alcohol monitoring

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: contingency management
Description: Participants can earn chance to win prizes for negative breath alcohol samples.
Study: NCT00568620

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Placement of nasogastric feeding tube
Description: Glucose tolerance test via nasogastric feeding tube~50 g glucose tolerance test on day 1; 50 g glucose tolerance test with 30 mL oil on day 2; Intravenous glucose tolerance test on day 3

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nasojejunal feeding tube
Description: Glucose tolerance test via nasojejunal feeding tube~50 g glucose tolerance test on day 1; 50 g glucose tolerance test with 30 mL oil on day 2; Intravenous glucose tolerance test on day 3
Study: NCT03532776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Podofilox Gel 0.5%
Description: Apply twice daily for three consecutive days, then discontinuing for four consecutive days, up to four treatment cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Condylox Topical Gel 0.5%
Description: Apply twice daily for three consecutive days, then discontinuing for four consecutive days, up to four treatment cycles

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Gel
Description: Apply twice daily for three consecutive days, then discontinuing for four consecutive days, up to four treatment cycles
Study: NCT02538939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium thiosulfate
Study: NCT02653586

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: program In Favor of Resilience Self
Description: A prevention program aiming at improve self-resilience ,self-esteem and body image, contains nine interactive activities, based on a cognitive dissonance method.
Study: NCT02866604

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sterofundin
Study: NCT02866604

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% saline
Study: NCT04518345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dubermatinib
Description: Given PO
Study: NCT04110054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-600918
Description: Tablets for oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to S-600918
Description: Tablets for oral administration
Study: NCT02011854

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rehabilitation
Description: rehabilitation,To treat five times a week,Total course is eight weeks

Intervention type: DEVICE
Group type: OTHER
Intervention: rehabilitation
Description: rehabilitation,To treat five times a week,Total course is eight weeks
Study: NCT03044080

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IncobotulinumtoxinA
Description: Three consecutive injections of 200-300 units of IncobotulinumtoxinA (Xeomin ®) under ultrasound guidance. The IncobotulinumtoxinA will be distributed according to the individual clinical pattern of spasticity: plantar flexor muscles (triceps sural: gastrocnemius and soleus), tibialis posterior, flexor digitorum longus.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OnabotulinumtoxinA
Description: ree consecutive injections of 200-300 units of OnabotulinumtoxinA (Botox ®) under ultrasound guidance. The BoNT/A will be distributed according to the individual clinical pattern of spasticity: plantar flexor muscles (triceps sural: gastrocnemius and soleus), tibialis posterior, flexor digitorum longus.
Study: NCT01489228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E1224
Description: 100 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E1224
Description: 100 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E1224
Description: 100 mg tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benznidazole
Description: 100mg tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablets
Study: NCT01670682

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ischia spinous fascia fixation
Description: Subjects of this group were submitted to surgical treatment with ischia spinous fascia fixation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modified Pelvic Floor Reconstruction Surgery with Mesh
Description: Subjects of this group were submitted to surgical treatment with Modified Total Pelvic Floor Reconstruction Surgery with Mesh.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: polypropylene mesh(Gynemesh)
Description: Pelvic floor reconstruction will be conducted using surgical mesh made from polypropylene.
Study: NCT03825510

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy
Description: All patients in this trial will be treated with fractionated Stereotactic body radiation therapy.~SBRT will be delivered to \<=3 sites in 3-5 fractions followed by administration of the specified immunotherapy agent (Nivolumab or Pembrolizumab). This approach will take advantage of the transient increase in antigen availability, increased antigen presentation and upregulation of PD-1 by tumor cells following ablative radiation therapy.
Study: NCT01022645

Intervention type: DEVICE
Intervention: Mirena (Levonorgestrel IUD)
Description: Release of intrauterine levonorgestrel for contraception, approved for up to 5 years' use
Study: NCT00604123

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo nasal spray twice daily for 2 weeks.
Study: NCT01022645

Intervention type: DEVICE
Intervention: Paragard (Copper IUD ) or Tubal Ligation
Description: Copper IUD placed to provide contraception for up to 10 years
Study: NCT00496678

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Navigation
Description: Cancer patients are randomly assigned to receive standard of care or the help of a trained person to navigated them through the cancer care system

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Cancer patients receive standard of care for their cancer treatment
Study: NCT01451398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technosphere® Insulin
Description: Technosphere® Insulin Inhalation Powder

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Technosphere Powder
Description: Placebo Comparator
Study: NCT04894539

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: DS5 electrical stimulator
Description: TENS

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DS5 electrical stimulator
Description: TENS

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DS5 electrical stimulator
Description: TENS
Study: NCT02334020

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mental Health First-aid
Description: 2 days training course providing information on severe mental illness, in order to make people able to support in situations of crisis

Intervention type: OTHER
Group type: OTHER
Intervention: Mental Health First-aid
Description: 2 days training course providing information on severe mental illness, in order to make people able to support in situations of crisis
Study: NCT03391557

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: UE
Description: All patients were examined by enhanced chest computed tomography (CT), the B-mode ultrasound and endobronchial ultrasound (EBUS)guided elastography before EBUS-TBNA. Each lymph node was assessed by describing the characteristics of the CT image (short diameter, texture, shape, boundary, mean CT value), B-mode ultrasound (short diameter, echo characteristic, shape, boundary) and ultrasound elastography (image type, grading score, strain rate, blue area ratio).
Study: NCT02289196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vx-006: 0,5mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vx-006: 1mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vx-006: 5mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vx-006: 10mg
Study: NCT04333979

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Drainage
Description: Using drain after operation
Study: NCT04279119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARQ-151- cream 0.3%
Description: ARQ-151 cream 0.3% applied to chronic plaque psoriasis lesions once a day for 2 weeks
Study: NCT02443337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3023414
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Necitumumab
Description: Administered IV
Study: NCT00392834

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: given subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: given subcutaneously
Study: NCT03044717

Intervention type: OTHER
Intervention: Nutrition survey
Description: Survey will be done prior to the initiation of the education

Intervention type: OTHER
Intervention: Educational Conference
Description: A prevention educational conference will be available to attend once every 5 weeks.

Intervention type: OTHER
Intervention: 3-hour nutrition module
Description: Nutrition module will be provided by the Gaples Institute to participants as part of this study. This will be completed online via e-mail
Study: NCT02836938

Intervention type: OTHER
Intervention: Collection of exhaled breath volatile organic compounds

Intervention type: OTHER
Intervention: Collection of exhaled breath volatile organic compounds

Intervention type: OTHER
Intervention: Collection of exhaled breath volatile organic compounds
Study: NCT01150318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of 131 iodine
Description: 100 mCi 131 iodine irradiation
Study: NCT02799368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CJ Plasma Solution A Injection
Description: Intravenous plasma solution (Chloride 90 mmoL/L) at 3 mL/kg over 1 hour pre-contrast, followed by the same solution intravenously at 1.5 mL/kg/hr for 4 hours. Intra-vascular low-osmolal or iso-osmolal contrast will be used.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CJ 0.9% Normal Saline Injection
Description: Intravenous plasma solution (Chloride 154 mmoL/L) at 3 mL/kg over 1 hour pre-contrast, followed by the same solution intravenously at 1.5 mL/kg/hr for 4 hours. Intra-vascular low-osmolal or iso-osmolal contrast will be used.
Study: NCT00807677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-901
Description: TAK-901 will be administered via IV infusion over a 3-hour period on Days 1,4,8,11,15,18,22, and 25 of each 28-day cycle.
Study: NCT02740387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTO-104
Study: NCT01181310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D: Donepezil 10 mg + Scopolamine 0.5 mg
Description: A single dose of donepezil 10 mg PO, plus a single dose of scopolamine 0.5 mg SQ.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D: Donepezil 10 mg + Scopolamine 0.5 mg
Description: A single dose of donepezil 10 mg PO, plus a single dose of scopolamine 0.5 mg SQ.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D: Donepezil 10 mg + Scopolamine 0.5 mg
Description: A single dose of donepezil 10 mg PO, plus a single dose of scopolamine 0.5 mg SQ.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D: Donepezil 10 mg + Scopolamine 0.5 mg
Description: A single dose of donepezil 10 mg PO, plus a single dose of scopolamine 0.5 mg SQ.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D: Donepezil 10 mg + Scopolamine 0.5 mg
Description: A single dose of donepezil 10 mg PO, plus a single dose of scopolamine 0.5 mg SQ.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D: Donepezil 10 mg + Scopolamine 0.5 mg
Description: A single dose of donepezil 10 mg PO, plus a single dose of scopolamine 0.5 mg SQ.
Study: NCT02547155

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia
Description: 8-12.5 mg of bupivacaine will be administered for spinal anesthesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia
Description: propofol induction, in combination with a muscle relaxant and inhalational gas
Study: NCT04811586

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: coronary revascularization
Description: to improve the blood supply for coronary arteries by using either percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: coronary revascularization
Description: to improve the blood supply for coronary arteries by using either percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG)
Study: NCT02011854

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Study: NCT03598868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Description: Augmentation : Vortioxetine 10 mg p.o. for week 1, Vortioxetine 5-20 mg p.o. for week 2,4,6.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Augmentation : Placebo for week 1,2,4,6
Study: NCT03056157

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptive Disclosure for Moral Injury and Loss
Description: AD-MIL is a manualized, 12-session individual psychotherapy designed to improve functioning and to reduce PTSD symptoms by facilitating Veterans doing corrective things in their life to heal and repair traumatic loss and moral injuries. The change agents are: (1) emotional-processing of traumatic loss and moral injuries and motivating a healing and action plan by writing therapeutic letters (e.g., to a lost unit member, to victims of personal transgressions, to people who transgressed); (2) skills training and behavioral contracting to improve functioning and targeting moral injury- and traumatic loss-related psychological and behavioral obstacles to positive and potentially habilitative engagements in occupational, relationship, and family roles; and (3) teaching self- and other-compassion and mindfulness. The goal is to redress the functional impact of moral emotions (anger, shame).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Present Centered Therapy
Description: Participants randomized to the PCT arm will receive 12 sessions of therapy focused on day-to-day functional problems with no focus on trauma or re-visiting past experiences
Study: NCT01123135

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal ERT
Description: 1gm of estrogen vaginal cream \[EVC\] at bed time 3 times a week

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04280705

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The supplied placebo lyophilized formulation is identical in physical appearance to the active lyophilized formulation and contains the same inactive ingredients. Alternatively, a placebo of normal saline of equal volume may be given if there are limitations on matching placebo supplies.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remdesivir
Description: Drug Remdesivir is a single diastereomer monophosphoramidate prodrug designed for the intracellular delivery of a modified adenine nucleoside analog GS-441524. In addition to the active ingredient, the lyophilized formulation of Remdesivir contains the following inactive ingredients: water for injection, sulfobutylether beta-cyclodextrin sodium (SBECD), and hydrochloric acid and/or sodium hydroxide.
Study: NCT05362734

Intervention type: BEHAVIORAL
Intervention: obstetric outcomes after fresh versus cryopreserved embryo transfer
Description: measure of ongoing pregnancy rate, delivery rate, abortion rate, ectopic pregnancy rate, multiple birth rate, ovarian hyperstimulation syndrome incidence, drop out rate

Intervention type: BEHAVIORAL
Intervention: obstetric outcomes after fresh versus cryopreserved embryo transfer
Description: measure of ongoing pregnancy rate, delivery rate, abortion rate, ectopic pregnancy rate, multiple birth rate, ovarian hyperstimulation syndrome incidence, drop out rate
Study: NCT01181310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D: Donepezil 10 mg + Scopolamine 0.5 mg
Description: A single dose of donepezil 10 mg PO, plus a single dose of scopolamine 0.5 mg SQ.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D: Donepezil 10 mg + Scopolamine 0.5 mg
Description: A single dose of donepezil 10 mg PO, plus a single dose of scopolamine 0.5 mg SQ.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D: Donepezil 10 mg + Scopolamine 0.5 mg
Description: A single dose of donepezil 10 mg PO, plus a single dose of scopolamine 0.5 mg SQ.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D: Donepezil 10 mg + Scopolamine 0.5 mg
Description: A single dose of donepezil 10 mg PO, plus a single dose of scopolamine 0.5 mg SQ.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E: Combo: Donepezil 10 mg + MK-3134 25 mg + Scopolamine 0.5 mg
Description: A combination of single doses of all active drugs: donepezil 10 mg and MK-3134 25 mg PO, plus scopolamine, SQ.
Study: NCT00960141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: montelukast sodium
Description: montelukast 10 mg tablet, taken orally once daily at bed time for 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: loratadine
Description: loratadine 10 mg tablet, taken orally once daily at bed time for 2 weeks
Study: NCT01181310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E: Combo: Donepezil 10 mg + MK-3134 25 mg + Scopolamine 0.5 mg
Description: A combination of single doses of all active drugs: donepezil 10 mg and MK-3134 25 mg PO, plus scopolamine, SQ.
Study: NCT04096729

Intervention type: OTHER
Intervention: compression stockings
Description: patients will be prescribed compression therapy for varicose veins of the legs using compression stockings
Study: NCT00934830

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic (Amoxicillin)
Description: 500 mg, 3 times per day for 10 days
Study: NCT00960141

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo
Description: placebo tablet, taken orally once daily at bed time for 2 weeks
Study: NCT04037813

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic and hysteroscopic tubal occlusion for hydrosalpinx
Description: For hysteroscopic tubal occlusion group it will be done under general anesthesia using standard, rigid 4-mm hysteroscopy with a 30° forward-oblique lens and a 5.5-mm diagnostic sheath (Karl Storz , Germany). Uterine distension allowed a panoramic view of the uterine cavity and identification of the tubal ostia.The roller ball (Ball Electrode, unipolar, 5 Fr) will be used for the coagulation of the interstitial part of the tube and the uterine cornu area.~For laparoscopic tubal occlusion group it will be done under general anesthesia using bipolar coagulation and a proximal tubal cut.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic and hysteroscopic tubal occlusion for hydrosalpinx
Description: For hysteroscopic tubal occlusion group it will be done under general anesthesia using standard, rigid 4-mm hysteroscopy with a 30° forward-oblique lens and a 5.5-mm diagnostic sheath (Karl Storz , Germany). Uterine distension allowed a panoramic view of the uterine cavity and identification of the tubal ostia.The roller ball (Ball Electrode, unipolar, 5 Fr) will be used for the coagulation of the interstitial part of the tube and the uterine cornu area.~For laparoscopic tubal occlusion group it will be done under general anesthesia using bipolar coagulation and a proximal tubal cut.
Study: NCT00786513

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional antimicrobial susceptibility testing
Description: Subjects in this arm will be prescribed 14 days of an intravenous 2 drug antibiotic combination based on conventional planktonic antimicrobial susceptibility testing results.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biofilm antimicrobial susceptibility testing
Description: Subjects in this arm will be prescribed 14 days of an intravenous 2 drug antibiotic combination based on biofilm antimicrobial susceptibility testing results.
Study: NCT02352909

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Education on running training modifications depending on symptoms (decrease running speed, spread running volume throughout the week, run/walk intervals, avoid downhill and stairs running). Education about symptoms will also be provided.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Education on running training modifications depending on symptoms (decrease running speed, spread running volume throughout the week, run/walk intervals, avoid downhill and stairs running). Education about symptoms will also be provided.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Education on running training modifications depending on symptoms (decrease running speed, spread running volume throughout the week, run/walk intervals, avoid downhill and stairs running). Education about symptoms will also be provided.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise program
Description: A home-based program including strengthening and motor control exercises will be prescribed. The program will include 4 different phases of 2 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gait retraining
Description: Running gait will be modified to reduce knee loading while running (step frequency, impact, foot strike pattern).
Study: NCT02711865

Intervention type: BIOLOGICAL
Intervention: IGF1R antibody MK0646

Intervention type: OTHER
Intervention: Saline solution
Study: NCT03490045

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diaper Incentive
Description: A diaper incentive will be distributed to participants in the Intervention condition at 4-time points, which will coincide with the well-child visits that occur at 2-weeks, 2-months, 4-months, and 6-months. A follow-up assessment will also occur approximately 3 months after the family received their final distribution of diapers.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conditional Cash Transfer Condition
Description: Participants in the control condition will receive the cash equivalent value of the diapers distributed to the Experimental Condition for their participation at 4-time points, which will coincide with the well-child visits that occur at 2-weeks, 2-months, 4-months, and 6-months. A follow-up assessment will also occur approximately 3 months after the family received their final conditional cash transfer.